^
Association details:
| Biomarker: | MYC overexpression + BCL2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) + Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergic Effect of Histone Deacetylase Inhibitor Chidamide with Doxorubicin on Diffuse Large B-Cell Lymphoma with Double BCL2/MYC Expression
Published date:
11/01/2018
Excerpt:
Core needle biopsy of tumor samples of DLBCL with double BCL2/MYC expression were transplanted into immunodecient (NOD-SCID) mice to establish patient-derived xenograft (PDX) models....observed significant growth inhibition of xenografted tumors treated with chidamide combined with doxorubicin, as compared to those of the single treatment....chidamide is able to synergize with doxorubicin to inhibit the growth of DLBCL expressing high levels of MYC and BCL2 in PDX models.
DOI:
10.1182/blood-2018-99-114079
